Shares of Savient Pharmaceuticals Inc. (SVNT) climbed throughout the first hour of Wednesday's session, but traded in a range for the remainder of the day. The stock closed up by $0.66 at $13.09. Savient Pharmaceuticals Inc. rose above a narrow, one-week range Wednesday and closed at an 8-month high. The stock has experienced a surge in volume and share price in the last 2 weeks, following an FDA review of studies of the company's gout drug Krystexxa.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.